Results 281 to 290 of about 185,904 (310)

Treatment of Acute Myeloid Leukemia

2010
The acute myeloid leukemias (AML) represent a heterogeneous group of malignancies derived from the pluripotent hematopoietic stem cell. These leukemias are generally characterized by genetic lesions that result in a combination of defects causing unregulated proliferation of cells and defects in cellular maturation (Gilliland and Griffin 2002).
Gibson, B, Perentesis, J., Alonzo, T.A., Kaspers, G.J.L.   +3 more
openaire   +3 more sources

Decitabine for acute myeloid leukemia

Expert Review of Anticancer Therapy, 2012
Decitabine (Dacogen(®), Eisai Inc., NJ, USA) is a nucleoside analogue DNA methyltransferase inhibitor first synthesized and documented to have antileukemic efficacy over 40 years ago. Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of 20 mg/m(2) is now commonly utilized.
openaire   +3 more sources

Acute Myeloid Leukemia

New England Journal of Medicine, 2015
Hartmut, Döhner, Daniel J, Weisdorf, Clara D, Bloomfield   +2 more
openaire   +2 more sources

Venetoclax in acute myeloid leukemia

Expert Opinion on Investigational Drugs, 2023
Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +8 more
openaire   +2 more sources

Childhood Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2008
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire   +2 more sources

Restoring metabolism of myeloid cells reverses cognitive decline in ageing

Nature, 2021
Congcong Wang, Miles H Linde, Amit U Joshi   +2 more
exaly  

Immunohistochemistry in Acute Myeloid Leukemia

2017
The World Health Organization's Classification of Tumours of Haematopoietic and Lymphoid Tissues (Swerdlow et al. (eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. WHO Press, Lyon, 2008) created a classification scheme incorporating genetic, molecular, morphologic, and immunophenotypic characteristics.
openaire   +3 more sources

A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells

Cell, 2021
Ziyi Li, Sijin Cheng, Ranran Gao
exaly  

Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer

Cell, 2020
Lei Zhang, Ziyi Li, Wei Zhang
exaly  

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions

Frontiers in Oncology, 2020
Sherly Mardiana, Saar Gill
exaly